Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
Purpose. To evaluate antiangiogenic effect of local use of bevacizumab (anti-VEGF antibody) in patients with corneal neovascularization. Methods. Patients were divided into two groups. All patients suffered from some form of corneal neovascularization (NV). Patients in group A received 0.2–0.5 mL of...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2014/178132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549987460841472 |
|---|---|
| author | Deli Krizova Magdalena Vokrojova Katerina Liehneova Pavel Studeny |
| author_facet | Deli Krizova Magdalena Vokrojova Katerina Liehneova Pavel Studeny |
| author_sort | Deli Krizova |
| collection | DOAJ |
| description | Purpose. To evaluate antiangiogenic effect of local use of bevacizumab (anti-VEGF antibody) in patients with corneal neovascularization. Methods. Patients were divided into two groups. All patients suffered from some form of corneal neovascularization (NV). Patients in group A received 0.2–0.5 mL of bevacizumab solution subconjunctivally (concentration 25 mg/mL) in a single dose. Group A included 28 eyes from 27. Patients in group B applied bevacizumab eye drops twice daily (concentration 2.5 mg/mL) for two weeks. Group B included 38 eyes from 35 patients. We evaluated the number of corneal segments affected by NV, CDVA, and the incidence of complications and subjective complaints related to the treatment. The minimum follow-up period was six months. Results. By the 6-month follow-up, in group A the percentage reduction of the affected peripheral segments was 21.6% and of the central segments was 9.6%; in group B the percentage reduction of the central segments was 22.7% and of the central segments was 38.04%. In both groups we noticed a statistically significant reduction in the extent of NV. Conclusion. The use of bevacizumab seems to be an effective and safe method in the treatment of corneal neovascularization, either in the subconjunctival or topical application form. |
| format | Article |
| id | doaj-art-3c0540c8c5be40eb968224cb3d55aae0 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-3c0540c8c5be40eb968224cb3d55aae02025-02-03T06:07:54ZengWileyJournal of Ophthalmology2090-004X2090-00582014-01-01201410.1155/2014/178132178132Treatment of Corneal Neovascularization Using Anti-VEGF BevacizumabDeli Krizova0Magdalena Vokrojova1Katerina Liehneova2Pavel Studeny3Ophthalmology Department, 3rd Medical Faculty of Charles University and University Hospital Kralovske Vinohrady, Srobarova 50, 10034 Prague, Czech RepublicOphthalmology Department, 3rd Medical Faculty of Charles University and University Hospital Kralovske Vinohrady, Srobarova 50, 10034 Prague, Czech RepublicOphthalmology Department, 3rd Medical Faculty of Charles University and University Hospital Kralovske Vinohrady, Srobarova 50, 10034 Prague, Czech RepublicOphthalmology Department, 3rd Medical Faculty of Charles University and University Hospital Kralovske Vinohrady, Srobarova 50, 10034 Prague, Czech RepublicPurpose. To evaluate antiangiogenic effect of local use of bevacizumab (anti-VEGF antibody) in patients with corneal neovascularization. Methods. Patients were divided into two groups. All patients suffered from some form of corneal neovascularization (NV). Patients in group A received 0.2–0.5 mL of bevacizumab solution subconjunctivally (concentration 25 mg/mL) in a single dose. Group A included 28 eyes from 27. Patients in group B applied bevacizumab eye drops twice daily (concentration 2.5 mg/mL) for two weeks. Group B included 38 eyes from 35 patients. We evaluated the number of corneal segments affected by NV, CDVA, and the incidence of complications and subjective complaints related to the treatment. The minimum follow-up period was six months. Results. By the 6-month follow-up, in group A the percentage reduction of the affected peripheral segments was 21.6% and of the central segments was 9.6%; in group B the percentage reduction of the central segments was 22.7% and of the central segments was 38.04%. In both groups we noticed a statistically significant reduction in the extent of NV. Conclusion. The use of bevacizumab seems to be an effective and safe method in the treatment of corneal neovascularization, either in the subconjunctival or topical application form.http://dx.doi.org/10.1155/2014/178132 |
| spellingShingle | Deli Krizova Magdalena Vokrojova Katerina Liehneova Pavel Studeny Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab Journal of Ophthalmology |
| title | Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab |
| title_full | Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab |
| title_fullStr | Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab |
| title_full_unstemmed | Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab |
| title_short | Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab |
| title_sort | treatment of corneal neovascularization using anti vegf bevacizumab |
| url | http://dx.doi.org/10.1155/2014/178132 |
| work_keys_str_mv | AT delikrizova treatmentofcornealneovascularizationusingantivegfbevacizumab AT magdalenavokrojova treatmentofcornealneovascularizationusingantivegfbevacizumab AT katerinaliehneova treatmentofcornealneovascularizationusingantivegfbevacizumab AT pavelstudeny treatmentofcornealneovascularizationusingantivegfbevacizumab |